Five years of treatment with a potent, non-steroidal aromatase inhibitor, anastrozole, reduced the incidence of primary breast cancer in postmenopausal women at high risk for developing the disease, according to an analysis of the international, double-blind, randomised placebo controlled study. The results were presented at the 2013 San Antonio Breast Cancer Symposium (10-14 December) and published simultaneously in the journal Lancet. Read more here.
Study mentioned: Cuzick J, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet, Early Online Publication, 12 December 2013.
No comments:
Post a Comment